Researchers at Stanford University have identified GPR183, a metabolite-sensing receptor, as a pivotal target for enhancing the infiltration of immune cells into solid tumors. By introducing GPR183 into natural killer (NK) cells, the study demonstrated a significant improvement in their ability to penetrate tumors and combat cancer in mouse models. This advancement addresses a longstanding challenge in cancer immunotherapy: the difficulty of immune cells accessing the tumor microenvironment, which is often hostile and suppressive.

The study’s findings indicate that GPR183, along with other G protein-coupled receptors (GPCRs), allows NK cells to respond to the unique metabolic signatures produced by cancer cells. In vitro experiments confirmed that NK cells expressing GPR183 showed increased chemotaxis towards cancer cell-derived metabolites, leading to enhanced infiltration into tumor spheroids. In vivo, mice treated with GPR183-overexpressing NK cells exhibited significantly delayed tumor growth and improved survival rates compared to controls, highlighting the therapeutic potential of this approach. Notably, the combination of GPR183 with chimeric antigen receptor (CAR) technology further amplified the anti-tumor effects.

This research shifts the paradigm in cancer immunotherapy by emphasizing the role of metabolite-sensing receptors in immune cell engineering. It opens new avenues for developing therapies that not only target tumor antigens but also exploit the metabolic landscape of tumors to enhance immune cell recruitment and efficacy. The implications for drug development are profound, suggesting that integrating metabolic targeting strategies could lead to more effective treatments for solid tumors, particularly in overcoming barriers associated with the tumor microenvironment.

Source: lifespan.io